Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By Vtv Therapeutics, Which Cantex Licensed...
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By Vtv Therapeutics, Which Cantex Licensed...
Cantex Pharmaceuticals Receives FDA Orphan Drug Designation For Azeliragon For The Treatment Of Pancreatic Cancer; Azeliragon Was Discovered By And Originally Under Development For Alzheimer's Disease By Vtv Therapeutics, Which Cantex Licensed Worldwide Rights
Cantex Pharmaceuticals因阿舍利骨胺治療胰腺癌而獲得FDA孤兒藥物認定；阿舍利骨胺最初由Vtv Therapeutics開發用於治療阿爾茨海默病，Cantex獲得全球獨家授權。
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon's previous orphan drug designation for the treatment of glioblastoma, received in early 2023.
Cantex Pharmaceuticals是一家臨床階段的藥品公司，專注於開發治療癌症和其他緊急需要新治療方法的危及性疾病的變革性療法。今天，該公司宣佈，美國食品和藥物管理局（FDA）已授予Cantex的阿舍利骨胺孤兒藥物認定，這是一種耐受性良好的一日一次口服藥物，用於治療胰腺癌。此次新的阿舍利骨胺孤兒藥物認定是其早在2023年獲得的用於治療膠質母細胞瘤的孤兒藥物認定的補充。
譯文內容由第三人軟體翻譯。